Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic MDST
Time: 16:35:02
Mid Price: 5.25
Change Today: 0.00
Change % Today: 0.00
Fifty Two Week High: 17.00
Fifty Two Week Low: 3.88
Market Capital: 8.17
Period & price data
Period Price
Now: 5.25
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Software & Computer Services
Epic: MDST
News: Latest news
Web Site: Medicsight
Other Articles: 26-01-201012-11-200928-10-2009

Medicsight

Medicsight Plc is a UK-headquartered research driven developer of computer-aided detection (CAD) and image analysis software for the medical imaging market, engaged in the development and commercialization of medical imaging software, which analyses Computer Tomography (CT) scans for the early detection and measurement of colon cancer polyps and lung cancer lesions. The Company is also engaged in the research and development of other medical software applications and devices with potential applications in the medical imaging, detection and diagnosis sectors. On June 28, 2007, Medicsight PLC acquired the entire share capital of Medicexchange PTY Ltd from Medicexchange (International) Ltd.

CLICK HERE FOR FULL ANLAYSIS OF MEDICSIGHT
Thursday, June 25, 2009

Medicsight launches online ColonCAD visualisation product

company news image

Medicsight PLC (AIM: MDST), developer of Computer-Aided Detection (CAD) and image analysis software, said it has launched its online product, MedicRead 3.0 Colon.

MedicRead 3.0 Colon is Medicsight’s own visualisation platform, integrated with the ColonCAD software to help radiologists read computer tomography (CT) scans for the detection of colonic polyps, which may be the precursors of colon cancer. 

The online product is making CAD accessible to the global radiology community.

Chief executive Allan Rowley said: “The launch of our online MedicRead 3.0 Colon platform provides the company with an additional revenue stream.  It is the only visualisation workstation that can be accessed and downloaded online enabling the international radiology community to experience and take advantage of the clinical benefits of ColonCAD.”

Access to Medicsight's ColonCAD software is currently available through the company's partners' 3D visualisation platforms.

MedicRead 3.0 Colon is not currently available for sale in the US.

 

NewsNow icon AddThis Feed Button
Register here to be notified of future Medicsight articles.

Other Medicsight articles

More articles ►

Other Medicsight news

More news ►

Investors interested in Medicsight recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.